New attack plan for rare leukemia: CAR-T cells + stem cell transplant
NCT ID NCT05870917
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see if this powerful combination can safely control the disease and improve survival in 20 newly diagnosed patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anti-BCMA CAR-T cells (a type of immune cell therapy) combined with chemotherapy (bortezomib, lenalidomide, dexamethasone) and a stem cell transplant
- What this could lead to
- If successful, this approach could offer a powerful way to control or even eliminate plasma cell leukemia in newly diagnosed patients, potentially leading to longer remission.
- What could go wrong
- This is a very small, early-phase study with only 20 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and cell therapy, which can cause serious side effects like infections or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- New hope for rare blood cancer: QUANTUM trial tests targeted therapy after transplant
- New drug cocktail aims to beat myeloma
- Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers